<DOC>
	<DOCNO>NCT02215824</DOCNO>
	<brief_summary>The primary aim trial investigate safety 6 hour intraarterial infusion BIWH 3 ( pyro-Glu-rhMCP-1 ) patient severe peripheral arterial occlusive disease ( PAOD ) chronic Critical Limb Ischaemia ( Fontaine class III IV ) .</brief_summary>
	<brief_title>Investigation Safety , Pharmacokinetics Pharmacodynamics Different Doses BIWH 3 Patients With Chronic Critical Limb Ischaemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<criteria>Inclusion : Patient must severe PAOD Chronic Critical Limb Ischaemia , Fontaine class III ( ischaemic pain rest ) IV ( tissue ulceration gangrene ) due atherosclerotic disease Patient must &gt; = 18 year age Patient must give write informed consent Patient must life expectancy least six month Exclusion : Transient ischaemic attack ( TIA ) , cerebral vascular accident ( CVA ) , myocardial infarction ( MI ) episode unstable angina within past two month Ophthalmologic condition : moderate severe nonproliferative retinopathy , proliferative retinopathy , age relate maculopathy choroidal neovascularisation , macular edema , intraocular surgery within previous 6 month , retinal vein occlusion Presence clinically significant disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study ECG result outside reference range clinical relevance include , limited QTcB &gt; 480 msec , PR interval &gt; 240 msec , QRS interval &gt; 140 msec History malignant disease , positive result require cancer screen test , unless definitive subsequent evaluation cancer determine negative Patients increase risk colorectal cancer , include follow ( 1 ) colorectal cancer pr polyp firstdegree relative young 60 two firstdegree relative age , ( 2 ) family history familial adenomatous polyposis hereditary nonpolyposis colon cancer , ( 3 ) history adenomatous polyp , ( 4 ) history chronic inflammatory bowel disease ( chronic ulcerative colitis Crohn 's disease ) Abnormalities great two time upper limit normal follow laboratory value Visit 1 : alanineaminotransferase ( ALT ) , aspartateaminotransferase ( AST ) , gammaglutamyl transferase ( GGT ) , alkaline phosphatase lactic dehydrogenase ( LDH ) ; abnormality great 1.5 time upper limit normal total bilirubin white blood cell count Any concurrent infectious disease require treatment Severe renal insufficiency ( estimate creatinine clearance &lt; 30 mL/min ) Duffy antigen negative blood type coexist moderate severe renal insufficiency ( estimate creatinine clearance &lt; 80 mL/min ) , avoid potential risk significant increase monocyte chemoattractant protein1 ( MCP1 ) level Known glomerulonephritis , even creatinine clearance apparently normal Thrombocytopenia , i.e . platelet count &lt; 100,000 cells/Î¼l Visit 1 History drug alcohol abuse within past 2 two year active drug alcohol abuse , present alcohol intake three drink per day Inability comply protocol Treatment investigational drug within 30 day 5 halflives , whichever great Visit 2 Use cilostazol cilostazol therapy start within 2 month prior trial enrollment , plan initiation cilostazol therapy trial period . Patients cilostazol &gt; 2 month prior enrollment may enrol Inability discontinue intake coumadin completion treatment period . Patients coumadin must international normalised ratio ( INR ) &lt; 1.8 Visit 2 Previous enrollment trial Hypersensitivity allergy heparin , conventional angiographic contrast dye , magnetic resonance angiography ( MRA ) contrast Inability undergo MRA ( e.g . heart pacemaker , artificial heart valve , implanted neurostimulator , intrauterine device ( IUD ) , metallic ear implant , implant port deliver insulin , foreign implant metallic object bullet fragment , metal plate , pin , screw staple , joint replacement , penile implant ) Know HIVinfection Unwillingness take blood product Pregnancy ( exclude serum urine betahuman chorionic gonadotropintest woman childbearing potential ) breast feed Female childbearing potential ( 12 month postmenopausal surgically sterilize ) use one follow method birth control : hormonal contraceptive , oral injectable/implantable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>